Skip to main content
. 2024 Sep 25;13(9):2236–2253. doi: 10.21037/tlcr-24-291

Figure 3.

Figure 3

Survival analysis for MPE RFS in treatment-naïve NSCLC patients with MPE and EGFR-TKI treatment. (A) The association between intrapleural perfusion treatment at onset and RFS1. (B) The association between intrapleural perfusion treatment at the first MPE recurrence and RFS2. The association between prior systemic progression and RFS1 for (C) all the patients and (D) the patients with at least one MPE recurrence during follow-up. The association between the change of systemic treatment at the first MPE recurrence and RFS2 for (E) all the patients and (F) the patients with MPE recurrence as the first sign of progression/recurrence. RFS1: time from the onset to the first MPE recurrence; RFS2: time from first to second MPE recurrence. RFS, recurrence-free survival; MPE, malignant pleural effusion; NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.